Please login to the form below

Not currently logged in
Email:
Password:

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

After Lucentis setback, Novartis trumpets data on follow-up drug

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis

Latest news

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival Novartis. ... advance the duo into phase III in either AMD or diabetic macular oedema.

  • Lucentis claims speedy FDA review for myopia complication Lucentis claims speedy FDA review for myopia complication

    in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.

  • NICE backs Bayer’s Eylea as first-line BRVO treatment NICE backs Bayer’s Eylea as first-line BRVO treatment

    This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

  • NICE backs Bayer's Eylea in diabetic eye condition NICE backs Bayer's Eylea in diabetic eye condition

    Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO). ... It also represents Eylea's third NICE recommendation, following positive guidance for wet age-related macular

More from news
Approximately 8 fully matching, plus 43 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

A reflection of ESMO
Client Relationship Director Fabienne Wild from Ashfield Meetings & Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO)....
OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....

Infographics